300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Email
Photography
Payments
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Hospitality
Sports
Legal
eSports
Construction
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Theatre
Cannabis
Medical
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Recruiting
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
Web3
FinTech
Finance
Financial Services
Franchise
Social Media
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Mexico
Tajikistan
Russian Federation
Nigeria
Togo
Guinea
Nepal
Iran
Madagascar
Isle of Man
Pakistan
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Kenya
Marshall Islands
Malta
Luxembourg
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Morocco
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Canada
Malaysia
Portugal
Philippines
United Kingdom
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Spain
Albania
Argentina
Bangladesh
Angola
Europe
Belgium
Barbados
Jordan
Cyprus
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Qatar
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Hungary
Italy
Grenada
Israel
Iceland
Cambodia
Honduras
Belarus
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
PULS, VC Fund

PULS

VC Fund

Saint Charles, United States

PULS is a VC fund in Saint Charles focused on Biopharma and Health Care. PULS is the only company worldwide focused entirely on the development and production of DIN rail power supplies. We concentrate our engineering knowledge, resources and energy on one goal: To be the best in this technology. As a result of this focus, we set standards in terms of efficiency and quality that delight our customers.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries PULS invests in

BiopharmaHealth CareBiotechnologyPharmaceutical

Stages PULS invests in

Funding Round

Countries PULS invests in

Sweden

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

4 more contacts available

Investment Focus

Industry

  • Biopharma 1 (100%)
  • Health Care 1 (100%)
  • Biotechnology 1 (100%)
  • Pharmaceutical 1 (100%)

Team

NameTitleInvestmentsLinksEmail
Bernhard Erdl
Bernhard Erdl Founder & CEO
Founder & CEO Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Adenovir Pharma Adenovir Pharma
Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes.Adenovir Pharma was founded by researchers at the department of Virology, Umeå University, Sweden and P.U.L.S. AB which acts as an incubator and financer for early stage projects within life science. Adenovir Pharma islocated in Helsingborg Sweden in one of Europe’s premier biotechnology regions, Medicon Valley. The initial development has been conducted at the University of Lund, Department of Organic Chemistry and at the University of Umeå, Department of Virology and in collaboration with P.U.L.S. AB and external service providers.With unique patented technology and own product concepts, Adenovir Pharma aim to offer new treatments and business development opportunities to the pharmaceutical industry. The goal is to develop a new antiviral medicinal product for the treatment and prevention of epidemic keratoconjunctivities (EKC). $787K / Jun 15, 2010

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Email
Photography
Payments
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Hospitality
Sports
Legal
eSports
Construction
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Theatre
Cannabis
Medical
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Recruiting
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
Web3
FinTech
Finance
Financial Services
Franchise
Social Media
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Mexico
Tajikistan
Russian Federation
Nigeria
Togo
Guinea
Nepal
Iran
Madagascar
Isle of Man
Pakistan
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Kenya
Marshall Islands
Malta
Luxembourg
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Morocco
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Canada
Malaysia
Portugal
Philippines
United Kingdom
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Asia
Bermuda
Spain
Albania
Argentina
Bangladesh
Angola
Europe
Belgium
Barbados
Jordan
Cyprus
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Qatar
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Hungary
Italy
Grenada
Israel
Iceland
Cambodia
Honduras
Belarus
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does PULS invest in?

PULS invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact PULS?

Public channels for PULS include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at PULS?

The team at PULS includes Bernhard Erdl (Founder & CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
PULS PULS Find emails